154 related articles for article (PubMed ID: 29412822)
21. C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes.
Gault VA; Kerr BD; Irwin N; Flatt PR
Biochem Pharmacol; 2008 Jun; 75(12):2325-33. PubMed ID: 18455149
[TBL] [Abstract][Full Text] [Related]
22. Degradation, insulin secretion, and antihyperglycemic actions of two palmitate-derivitized N-terminal pyroglutamyl analogues of glucose-dependent insulinotropic polypeptide.
Irwin N; Green BD; Gault VA; Greer B; Harriott P; Bailey CJ; Flatt PR; O'Harte FP
J Med Chem; 2005 Feb; 48(4):1244-50. PubMed ID: 15715491
[TBL] [Abstract][Full Text] [Related]
23. A novel DPP IV-resistant C-terminally extended glucagon analogue exhibits weight-lowering and diabetes-protective effects in high-fat-fed mice mediated through glucagon and GLP-1 receptor activation.
Lynch AM; Pathak N; Pathak V; O'Harte FP; Flatt PR; Irwin N; Gault VA
Diabetologia; 2014 Sep; 57(9):1927-36. PubMed ID: 24962667
[TBL] [Abstract][Full Text] [Related]
24. Biological and functional characteristics of a novel low-molecular weight antagonist of glucose-dependent insulinotropic polypeptide receptor, SKL-14959, in vitro and in vivo.
Nakamura T; Tanimoto H; Mizuno Y; Tsubamoto Y; Noda H
Diabetes Obes Metab; 2012 Jun; 14(6):511-7. PubMed ID: 22192426
[TBL] [Abstract][Full Text] [Related]
25. Degradation, cyclic adenosine monophosphate production, insulin secretion, and glycemic effects of two novel N-terminal Ala2-substituted analogs of glucose-dependent insulinotropic polypeptide with preserved biological activity in vivo.
Gault VA; O'Harte FP; Harriott P; Flatt PR
Metabolism; 2003 Jun; 52(6):679-87. PubMed ID: 12800091
[TBL] [Abstract][Full Text] [Related]
26. GIP(Lys16PAL) and GIP(Lys37PAL): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential.
Irwin N; O'Harte FP; Gault VA; Green BD; Greer B; Harriott P; Bailey CJ; Flatt PR
J Med Chem; 2006 Feb; 49(3):1047-54. PubMed ID: 16451070
[TBL] [Abstract][Full Text] [Related]
27. (D-Ser2)Oxm[mPEG-PAL]: a novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions.
Kerr BD; Flatt PR; Gault VA
Biochem Pharmacol; 2010 Dec; 80(11):1727-35. PubMed ID: 20735990
[TBL] [Abstract][Full Text] [Related]
28. N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity.
Green BD; Mooney MH; Gault VA; Irwin N; Bailey CJ; Harriott P; Greer B; O'Harte FP; Flatt PR
J Endocrinol; 2004 Mar; 180(3):379-88. PubMed ID: 15012592
[TBL] [Abstract][Full Text] [Related]
29. Evidence for inhibitory autocrine effects of proinsulin C-peptide on pancreatic β-cell function and insulin secretion.
McKillop AM; Ng MT; Abdel-Wahab YH; Flatt PR
Diabetes Obes Metab; 2014 Oct; 16(10):937-46. PubMed ID: 24702738
[TBL] [Abstract][Full Text] [Related]
30. A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release.
Chu ZL; Carroll C; Alfonso J; Gutierrez V; He H; Lucman A; Pedraza M; Mondala H; Gao H; Bagnol D; Chen R; Jones RM; Behan DP; Leonard J
Endocrinology; 2008 May; 149(5):2038-47. PubMed ID: 18202141
[TBL] [Abstract][Full Text] [Related]
31. Dual modulation of GIP and glucagon action by the low molecular weight compound 4-hydroxybenzoic acid 2-bromobenzylidene hydrazide.
Franklin ZJ; McDonnell B; Montgomery IA; Flatt PR; Irwin N
Diabetes Obes Metab; 2011 Aug; 13(8):742-9. PubMed ID: 21418501
[TBL] [Abstract][Full Text] [Related]
32. Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide.
Gault VA; O'Harte FP; Harriott P; Flatt PR
Biochem Biophys Res Commun; 2002 Feb; 290(5):1420-6. PubMed ID: 11820780
[TBL] [Abstract][Full Text] [Related]
33. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.
Jin CH; Chae SY; Son S; Kim TH; Um KA; Youn YS; Lee S; Lee KC
J Control Release; 2009 Feb; 133(3):172-7. PubMed ID: 18977255
[TBL] [Abstract][Full Text] [Related]
34. Biological activity and antidiabetic potential of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide, GIP(1-16) and (Pro3)GIP(1-16).
Irwin N; Green BD; Parker JC; Gault VA; O'Harte FP; Flatt PR
Regul Pept; 2006 Jul; 135(1-2):45-53. PubMed ID: 16675042
[TBL] [Abstract][Full Text] [Related]
35. Glucagon-like peptide 1-potentiated insulin secretion and proliferation of pancreatic β-cells.
Ma X; Guan Y; Hua X
J Diabetes; 2014 Sep; 6(5):394-402. PubMed ID: 24725840
[TBL] [Abstract][Full Text] [Related]
36. Characterisation of structurally modified analogues of glucagon as potential glucagon receptor antagonists.
O'Harte FP; Franklin ZJ; Rafferty EP; Irwin N
Mol Cell Endocrinol; 2013 Dec; 381(1-2):26-34. PubMed ID: 23891841
[TBL] [Abstract][Full Text] [Related]
37. Activation of GPR119 by fatty acid agonists augments insulin release from clonal β-cells and isolated pancreatic islets and improves glucose tolerance in mice.
Moran BM; Abdel-Wahab YH; Flatt PR; McKillop AM
Biol Chem; 2014 Apr; 395(4):453-64. PubMed ID: 24323890
[TBL] [Abstract][Full Text] [Related]
38. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR
J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370
[TBL] [Abstract][Full Text] [Related]
39. Characterization and biological actions of N-terminal truncated forms of glucose-dependent insulinotropic polypeptide.
Kerr BD; Flatt AJ; Flatt PR; Gault VA
Biochem Biophys Res Commun; 2011 Jan; 404(3):870-6. PubMed ID: 21184739
[TBL] [Abstract][Full Text] [Related]
40. Detrimental actions of metabolic syndrome risk factor, homocysteine, on pancreatic beta-cell glucose metabolism and insulin secretion.
Patterson S; Flatt PR; Brennan L; Newsholme P; McClenaghan NH
J Endocrinol; 2006 May; 189(2):301-10. PubMed ID: 16648297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
